Main Menu
Main Menu
The news items below include announcements from companies in the Brain Tumor Investment Fund™ portfolio. These announcements are produced by the companies themselves. Their content, including any forward-looking or investigational claims, is the responsibility of the issuing company. Brain Tumor Investment Fund™ and National Brain Tumor Society do not specifically endorse or verify third-party statements, and investigational therapies referenced have not been proven safe or effective and are not approved by the U.S. Food and Drug Administration.
Alpheus Medical Opens Enrollment in New Clinical Trial for Butterfly Glioblastoma Alpheus Medical, a Brain Tumor Investment Fund™ portfolio company, has opened enrollment in the Alpheus Butterfly trial (NCT07862647). The multicenter study is testing the company’s investigational PoMA™ therapy in people with newly diagnosed butterfly glioblastoma (GBM). Butterfly GBM crosses the corpus callosum into both hemispheres of the brain. Because of that, patients with it are […] October 12, 2026
MimiVax reports results from phase 2b SURVIVE trial of SurVaxM in newly diagnosed glioblastoma MimiVax, a Brain Tumor Investment Fund™ portfolio company, and Roswell Park Comprehensive Cancer Center have reported results from SURVIVE (NCT05163080). The trial is a phase 2b randomized, double-blind, placebo-controlled study of the company’s investigational vaccine, SurVaxM, in people with newly diagnosed glioblastoma (GBM), with 233 evaluable patients at 11 U.S. cancer centers. According to the […] October 8, 2026
Portfolio Spotlight: Alpheus Medical One of the things we look for in a BTIF portfolio company is a genuinely novel approach to treating brain tumors. Alpheus Medical is one of those companies. A Different Kind of Treatment Alpheus is developing a type of drug-led therapy it calls “Porphyrin Metabolite Activation” or, simply “PoMA.” The approach builds on the FDA-approved […] June 9, 2026
Trogenix doses first patient in Phase I/II glioblastoma gene therapy trial Trogenix, a Brain Tumor Investment Fund™ portfolio company, has announced that the first patient has been dosed in ADePT, a phase I/II clinical trial of its investigational gene therapy TGX-007 for newly diagnosed and recurrent glioblastoma (GBM). The trial is now open at two sites: NHS Lothian in the United Kingdom and Ohio State University […] June 2, 2026
FOX 26 Houston: Diakonos’s Experimental Immunotherapy for Glioblastoma Shows Promising Survival Gains in Early Trials FOX 26 Houston reports on early clinical data from BTIF portfolio company Diakonos Oncology’s investigational dendritic cell immunotherapy for glioblastoma. The report highlights phase I trial results and features a patient currently receiving the treatment. Diakonos’s vaccine therapy — known as Dubodencel or DOC1021 — uses a patient’s own tumor DNA to prime dendritic cells, […] April 16, 2026